| Literature DB >> 36130770 |
James R Bundred1,2, Sarah Michael3,4, Beth Stuart5, Ramsey I Cutress5,6, Kerri Beckmann7, Bernd Holleczek8,9, Jane E Dahlstrom10, Jacqui Gath11, David Dodwell12, Nigel J Bundred13,4.
Abstract
OBJECTIVE: To determine if margin involvement is associated with distant recurrence and to determine the required margin to minimise both local recurrence and distant recurrence in early stage invasive breast cancer.Entities:
Mesh:
Year: 2022 PMID: 36130770 PMCID: PMC9490551 DOI: 10.1136/bmj-2022-070346
Source DB: PubMed Journal: BMJ ISSN: 0959-8138
Fig 1PRISMA flowchart showing selection of abstracts and studies from searching through to inclusion in the meta-analysis and studies excluded with reasons. BCS=breast conserving surgery
Fig 2Forest plots of margin involvement and distant recurrence, showing tumour on ink versus tumour not at ink; tumour on ink or tumour at <1 mm defined versus wide margins >1 mm; tumour on ink and <2 mm margin versus wide margin >2 mm; tumour between 0.1 and 1 mm from ink versus wide margins >2 mm; tumour 0.1-2 mm from ink versus wider margins >2 mm; tumour 1.1-2 mm from ink margin versus margins >2 mm from ink. DR=distant recurrence; RE=random effects; df=degrees of freedom; NS=not stated
Specific characteristics of studies reporting on margin status and distant recurrence or overall survival outcomes. Data are number (%), unless otherwise specified
| Study | P/C | TOI | Total | %P/C | Radiotherapy | Adjuvant chemotherapy | Hormone therapy | Re-excision | Grade 3 | N0 | Factors adjusted*; adequate adjustment† |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Voogd 2001 | 165 | 165 | 633 | 26.0 | 633 (100) | 272 (43) | NS | NS | 311 (49.1) | 543 (85.8) | Age, T stage, N stage, histology, grade, vascular invasion; N |
| Goldstein 2003 | 269 | 269 | 602 | 44.7 | 602 (100) | 95 (15.8) | 224 (37.2) | 441 (73.2) | 174 (39.9) | 441 (73.3) | Age, T stage; N |
| Ewertz 2008 | 192 | — | 3647 | 5.3 | 3506 (96.1) | 1250 (34.2) | 2232 (61.2) | NS | NS | 2649 (72.6) | Age, T stage, N stage, radiotherapy; N |
| Behm 2013 | 206 | 43 | 2300 | 9.0 | 1457 (63.3) | 1112 (48.3) | 1747 (75.9) | 1452 (63.1) | 717 (31.2) | 1325 (57.6) | Age, radiotherapy, grade, nodal involvement, ER/PR status, hormone therapy, chemotherapy; Y |
| Bodilsen 2016 | 39 | — | 1519 | 2.6 | 1519 (100) | 616 (40.6) | 912 (60) | 178 (11.7) | 332 (21.9) | 934 (61.5) | Age, histology, N stage, vascular invasion, re-excision, chemotherapy, boost radiotherapy; N |
| Bosma 2016 | 1155 | 621 | 8485 | 13.6 | 8485 (100) | 1858 (22) | 2567 (30) | 761 (8.9) | 2061 (29) | 4964 (66) | Age, T stage, N stage, histology, grade, chemotherapy, radiotherapy; Y |
| Maishman 2017 | 239 | 102 | 1055 | 17.1 | 1055 (96) | 1055 (100) | 839 (60.1) | 290 (20.7) | 848 (60.8) | 837 (60) | Age, T stage, N stage, histology, boost dose radiotherapy, focality; Y |
| Tyler 2018 | 1622 | — | 10 863 | 14.9 | 10 863 (100) | 3950 (36.3) | 8073 (74.3) | 1622 (14.9) | 3260 (30) | 7720 (71.1) | Age, grade, vascular invasion, N stage, radiotherapy, histology, systemic adjuvant therapy; Y |
| Holleczek 2019 | 188 | 188 | 3786 | 4.9 | 3786 (100) | 70% of node positive | 7955 (85) | NS | 1060 (28) | 3435 (90.7) | Age, T stage, N stage, grade, molecular phenotype; Y |
| Livi 2007 | 303 | 303 | 3834 | 7.9 | 3834 (100) | 920 (24) | 1796 (47) | NS | NS | 2701 (70.4) | Age, T stage, N stage, chemotherapy; N |
| Totals | 2920 | — | 24 745 | 11.8 | 23 705 (95.8) | 8078 (39.7) | 14 027 (69.0) | 3983 (23.8) | 6528 (31.9) | 17 884 (72.2) | — |
ER=oestrogen receptor; PR=progesterone receptor; TOI=number of patients with tumour at ink; P/C=Number of patients with tumour at ink or close (within a defined margin distance); %P/C=The percentage of the total cohort with patients with tumour at ink or within a defined margin distance; RT=Radiotherapy; HT+=Hormone therapy; N0=lymph node negative patients; NS=not stated in paper.
Other than margin status.
To be adequately adjusted a study must adjust for age, tumour stage (T/N), grade, chemotherapy, radiotherapy OR must contain exclusively patients (>95%) receiving chemotherapy/radiotherapy if not adjusting for these covariates.
Tabulation of results by different outcomes and margin distance models, along with outcomes from assessment of evidence quality and risk of bias summaries
| Outcomes and subgroup | No | HR (95% CI) | P value | I2 | Egger’s P value | Risk of bias | Quality of evidence |
|---|---|---|---|---|---|---|---|
|
| |||||||
| Model one, TOI | |||||||
| Overall | 5 | 2.10 (1.65 to 2.69) | <0.001 | 38 | 0.43 | Low | Moderate ⨁⨁⨁◯ |
| Adjusted only | 5 | 2.10 (1.65 to 2.69) | <0.001 | 38 | 0.43 | ||
| Adequately adjusted* | 3 | 2.41 (1.81 to 3.21) | <0.001 | 31 | NA | ||
| Published after 2010 | 5 | 2.10 (1.65 to 2.69) | <0.001 | 38 | 0.43 | ||
| Model two, TOI or close | |||||||
| Overall | 3 | 1.53 (1.17 to 1.99) | 0.001 | 0 | NA | Low | Moderate ⨁⨁⨁◯ |
| Adjusted only | 2 | 1.56 (1.19 to 2.06) | 0.002 | 0 | NA | ||
| Adequately adjusted* | 2 | 1.56 (1.19 to 2.06) | 0.002 | 0 | NA | ||
| Published after 2010 | 3 | 1.53 (1.17 to 1.99) | 0.001 | 0 | NA | ||
| Model two, TOI or close | |||||||
| Overall | 3 | 1.46 (1.18 to 1.80) | <0.001 | 0 | NA | Low | Moderate ⨁⨁⨁◯ |
| Adjusted only | 3 | 1.46 (1.18 to 1.80) | <0.001 | 0 | NA | ||
| Adequately adjusted* | 3 | 1.46 (1.18 to 1.80) | <0.001 | 0 | NA | ||
| Published after 2010 | 3 | 1.46 (1.18 to 1.80) | <0.001 | 0 | NA | ||
| Model three, close | |||||||
| Overall | 3 | 1.38 (1.13 to 1.69) | 0.001 | 0 | NA | Low | Moderate ⨁⨁⨁◯ |
| Adjusted only | 2 | 1.39 (1.14 to 1.7) | 0.001 | 0 | NA | ||
| Adequately adjusted* | 2 | 1.39 (1.14 to 1.7) | 0.001 | 0 | NA | ||
| Published after 2010 | 3 | 1.38 (1.13 to 1.69) | 0.001 | 0 | NA | ||
| Model three, close | |||||||
| Overall | 2 | 1.31 (0.97 to 1.78) | 0.08 | 0 | NA | Low | Moderate ⨁⨁⨁◯ |
| Model three, close | |||||||
| Overall | 2 | 1.40 (1.03 to 1.91) | 0.03 | 0 | NA | Low | Moderate ⨁⨁⨁◯ |
|
| |||||||
| Model one, TOI | |||||||
| Overall | 2 | 1.61 (1.19 to 2.17) | <0.001 | 41 | NA | Low | Moderate ⨁⨁⨁◯ |
| Adjusted only | 1 | 1.92 (1.34 to 2.76) | <0.001 | NA | NA | ||
| Adequately adjusted* | 1 | 1.92 (1.34 to 2.76) | <0.001 | NA | NA | ||
| Published after 2010 | 1 | 1.92 (1.34 to 2.76) | <0.001 | NA | NA | ||
| Model two, TOI or close | |||||||
| Overall | 3 | 1.32 (1.01 to 1.73) | 0.05 | 69 | NA | Low | Moderate ⨁⨁⨁◯ |
| Adjusted only | 3 | 1.32 (1.01 to 1.73) | 0.05 | 69 | NA | ||
| Adequately adjusted* | 3 | 1.32 (1.01 to 1.73) | 0.05 | 69 | NA | ||
| Published after 2010 | 3 | 1.32 (1.01 to 1.73) | 0.05 | 69 | NA | ||
|
| |||||||
| Model one, TOI | |||||||
| Overall | 12 | 1.98 (1.66 to 2.36) | <0.001 | 0 | 0.33 | Moderate | Low ⨁⨁◯◯ |
| Adjusted only | 10 | 1.92 (1.59 to 2.32) | <0.001 | 0 | 0.48 | ||
| Adequately adjusted* | 4 | 1.98 (1.19 to 3.3) | 0.008 | 56 | 0.86 | ||
| Published after 2010 | 8 | 2.11 (1.62 to 2.73) | <0.001 | 22 | 0.39 | ||
| Model two, TOI or close | |||||||
| Overall | 4 | 1.86 (1.14 to 3.04) | 0.01 | 41 | 0.55 | Moderate | Low ⨁⨁◯◯ |
| Adjusted only | 2 | 2.22 (0.59 to 8.33) | 0.24 | 74 | NA | ||
| Adequately adjusted* | 1 | 1.23 (0.63 to 2.39) | 0.54 | NA | NA | ||
| Published after 2010 | 4 | 1.86 (1.14 to 3.04) | 0.01 | 41 | 0.55 | ||
| Model two, TOI or close | |||||||
| Overall | 13 | 1.86 (1.52 to 2.28) | <0.001 | 35 | 0.03 | Moderate | Low ⨁⨁◯◯ |
| Adjusted only | 10 | 1.95 (1.46 to 2.59) | <0.001 | 46 | 0.01 | ||
| Adequately adjusted* | 6 | 1.66 (1.27 to 2.17) | <0.001 | 39 | 0.84 | ||
| Published after 2010 | 13 | 1.86 (1.52 to 2.28) | <0.001 | 35 | 0.03 | ||
| Model three, close | |||||||
| Overall | 6 | 2.09 (1.39 to 3.13) | <0.001 | 55 | 0.56 | Moderate | Low ⨁⨁◯◯ |
| Adjusted only | 4 | 2.14 (1.33 to 3.47) | 0.001 | 57 | 0.78 | ||
| Adequately adjusted* | 2 | 2.10 (0.92 to 4.77) | 0.08 | 81 | NA | ||
| Published after 2010 | 5 | 1.93 (1.28 to 2.91) | 0.001 | 56 | 0.86 | ||
| Model three, close | |||||||
| Overall | 3 | 1.60 (1.13 to 2.25) | 0.007 | 0 | 0.27 | Moderate | Low ⨁⨁◯◯ |
| Adjusted only | 3 | 1.60 (1.13 to 2.25) | 0.007 | 0 | 0.27 | ||
| Adequately adjusted* | 1 | 1.42 (0.78 to 2.58) | 0.25 | 0 | NA | ||
| Published after 2010 | 2 | 1.31 (0.79 to 2.17) | 0.29 | 0 | NA | ||
| Model three, close | |||||||
| Overall | 1 | 1.81 (0.95 to 3.45) | 0.07 | NA | NA | Moderate | Low ⨁⨁◯◯ |
Adjusted only subgroup contains only papers with adjusted summary estimates (hazard ratios) for the outcome (distant recurrence, local recurrence, or overall survival). CI=confidence intervals; Egger’s P value=P value from Egger’s regression analyses of publication biases; HR=hazard ratio; NA=not available. TOI=tumour on ink.
To be adequately adjusted a study must adjust for age, tumour stage (T/N), grade, chemotherapy, radiotherapy, or must contain exclusively patients (>95%) receiving chemotherapy or radiotherapy if not adjusting for these covariates.
Fig 3Forest plots of margin involvement and local recurrence: tumour on ink versus tumour not at ink; tumour on ink or tumour at <1 mm defined versus wide margins >1 mm; tumour on ink and <2 mm margin versus wide margin >2 mm; tumour 0.1-1 mm from ink versus margins >2 mm; tumour 0.1-2 mm from ink compared with wider margins >2 mm; tumour 1.1-2 mm from ink margin compared with margins >2 mm from ink. LR=local recurrence; df=degrees of freedom